[
  {
    "ts": null,
    "headline": "What Is the Intent Behind AbbVie's Recent Acquisition Spree?",
    "summary": "ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.",
    "url": "https://finnhub.io/api/news?id=eb09f7dbdfaa9734efc1d66217ea368d21397abd4e2c31f020e5200ae80b5436",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756307820,
      "headline": "What Is the Intent Behind AbbVie's Recent Acquisition Spree?",
      "id": 136539545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.",
      "url": "https://finnhub.io/api/news?id=eb09f7dbdfaa9734efc1d66217ea368d21397abd4e2c31f020e5200ae80b5436"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For September 2025",
    "summary": "Discover top Dividend Aristocrats for 2025! Explore undervalued picks with 10%+ annualized returns, robust payout growth, and reliable income opportunities.",
    "url": "https://finnhub.io/api/news?id=6fa72cb3c60dde4a3180ad17c2df91d58aa59ccc934dd1f72334c03464c353e0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756303789,
      "headline": "Best Dividend Aristocrats For September 2025",
      "id": 136539374,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1962656730/image_1962656730.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover top Dividend Aristocrats for 2025! Explore undervalued picks with 10%+ annualized returns, robust payout growth, and reliable income opportunities.",
      "url": "https://finnhub.io/api/news?id=6fa72cb3c60dde4a3180ad17c2df91d58aa59ccc934dd1f72334c03464c353e0"
    }
  },
  {
    "ts": null,
    "headline": "Will Camzyos Strengthen BMY's Cardiovascular Portfolio?",
    "summary": "Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.",
    "url": "https://finnhub.io/api/news?id=6dd2c50f4ff131f4e4e9576cb60563591f4426ac4f6caf4c37bf354484d278e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756303500,
      "headline": "Will Camzyos Strengthen BMY's Cardiovascular Portfolio?",
      "id": 136539572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.",
      "url": "https://finnhub.io/api/news?id=6dd2c50f4ff131f4e4e9576cb60563591f4426ac4f6caf4c37bf354484d278e3"
    }
  },
  {
    "ts": null,
    "headline": "Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma",
    "summary": "The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market growth is propelled by insights into immune mechanisms and increasing awareness among healthcare providers. Emerging diagnostic tools and biologic therapies, such as monoclonal antibodies, enhance trea",
    "url": "https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756284600,
      "headline": "Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma",
      "id": 136536324,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market growth is propelled by insights into immune mechanisms and increasing awareness among healthcare providers. Emerging diagnostic tools and biologic therapies, such as monoclonal antibodies, enhance trea",
      "url": "https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be"
    }
  },
  {
    "ts": null,
    "headline": "Autism Spectrum Disorder Market Research Report 2025-2035 | Expansion Spurred by Rising Prevalence, AI-Powered Diagnostics, Telehealth Expansion, and Adoption of Evidence-Based Therapies",
    "summary": "Autism Spectrum Disorder (ASD) involves challenges in social interaction, communication, and repetitive behaviors. Early diagnosis is enhanced by advancements in screening tools and genetic testing, increasing the demand for personalized therapies. FDA-approved medications for irritability in ASD, Risperidone and Aripiprazole, dominate the market. Challenges include symptom variability and limited care access. Nonetheless, government initiatives and research investment foster growth. North Ameri",
    "url": "https://finnhub.io/api/news?id=fd997815a653213df602c31c2d03e9d6818c7bc6bed0987151aae7401d0f2e9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756284240,
      "headline": "Autism Spectrum Disorder Market Research Report 2025-2035 | Expansion Spurred by Rising Prevalence, AI-Powered Diagnostics, Telehealth Expansion, and Adoption of Evidence-Based Therapies",
      "id": 136536325,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Autism Spectrum Disorder (ASD) involves challenges in social interaction, communication, and repetitive behaviors. Early diagnosis is enhanced by advancements in screening tools and genetic testing, increasing the demand for personalized therapies. FDA-approved medications for irritability in ASD, Risperidone and Aripiprazole, dominate the market. Challenges include symptom variability and limited care access. Nonetheless, government initiatives and research investment foster growth. North Ameri",
      "url": "https://finnhub.io/api/news?id=fd997815a653213df602c31c2d03e9d6818c7bc6bed0987151aae7401d0f2e9e"
    }
  },
  {
    "ts": null,
    "headline": "Citi Lifts Johnson & Johnson (JNJ) Price Target to $200 on MedTech Strength",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the top stocks to buy and hold forever. Founded in 1887, the company has built a global brand and a portfolio of patent-protected drugs in oncology, immunology, neuroscience, and infectious diseases. Combined with its strong distribution network, these factors provide Johnson & Johnson (NYSE:JNJ) with a durable competitive advantage and […]",
    "url": "https://finnhub.io/api/news?id=e564a2dff833fd68460ffe98dd586db5fdc044d05085c83a4eeae35505c28ba5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756266835,
      "headline": "Citi Lifts Johnson & Johnson (JNJ) Price Target to $200 on MedTech Strength",
      "id": 136535015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the top stocks to buy and hold forever. Founded in 1887, the company has built a global brand and a portfolio of patent-protected drugs in oncology, immunology, neuroscience, and infectious diseases. Combined with its strong distribution network, these factors provide Johnson & Johnson (NYSE:JNJ) with a durable competitive advantage and […]",
      "url": "https://finnhub.io/api/news?id=e564a2dff833fd68460ffe98dd586db5fdc044d05085c83a4eeae35505c28ba5"
    }
  }
]